• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy
CONCLUSIONS: In stabilised acute myocardial infarction patients, unguided de-escalation from ticagrelor to clopidogrel was associated with a lower rate of net adverse clinical outcomes irrespective of HBR status. The effect of de-escalation of P2Y12 inhibition on reducing haemorrhagic events was greater in patients with HBR.PMID:37724337 | DOI:10.4244/EIJ-D-23-00427
Source: EuroIntervention - September 19, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Min Chul Kim Sung Gyun Ahn Kyung Hoon Cho Doo Sun Sim Young Joon Hong Ju Han Kim Myung Ho Jeong Jun-Won Lee Young-Jin Youn Hee-Yeol Kim Ki-Dong Yoo Doo-Soo Jeon Eun-Seok Shin Young-Hoon Jeong Kiyuk Chang Youngkeun Ahn Source Type: research

Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial
EuroIntervention. 2023 Aug 22:EIJ-D-23-00206. doi: 10.4244/EIJ-D-23-00206. Online ahead of print.ABSTRACTAbout one-third of patients undergoing transcatheter aortic valve implantation (TAVI) use oral anticoagulants (OAC), mainly due to atrial fibrillation. General guidelines advise interrupting OAC in patients with a high risk of bleeding undergoing interventions. However, preliminary observational data suggest that the continuation of OAC during TAVI is safe and may reduce the risk of periprocedural thromboembolic events. The Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter ...
Source: EuroIntervention - August 22, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Dirk-Jan van Ginkel Willem L Bor Christophe L F Dubois Hugo M Aarts Maxim J P Rooijakkers Kees H van Bergeijk Liesbeth Rosseel Leo Veenstra Ole De Backer Nicolas M Van Mieghem Frank van der Kley Adriaan Wilgenhof Remigio Leonora Jonathan Halim Carl E Scho Source Type: research

P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
EuroIntervention. 2023 Jun 12:EIJ-D-23-00125. doi: 10.4244/EIJ-D-23-00125. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open...
Source: EuroIntervention - June 12, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Patricia O Guimar ães Marcelo Franken Caio A M Tavares Fabio S Silveira Murillo O Antunes Ricardo R Bergo Rodrigo M Joaquim Jessica C S Hirai Pedro B Andrade Fabio G Pitta Jos é Mariani Bruno R Nascimento Jo ão E T de Paula Marcos S Silveira Tiberio A Source Type: research

Prosthesis Choice in Dialysis Patients Undergoing Mitral Valve Replacement
CONCLUSIONS: MVR in dialysis patients carries significant morbidity and increased mid-term mortality. Decreased life-expectancy should be considered in the tailoring of prosthesis choice to dialysis-dependent patients.PMID:37245789 | DOI:10.1016/j.athoracsur.2023.05.015
Source: The Annals of Thoracic Surgery - May 28, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Amit Iyengar Cindy Song Noah Weingarten David Rekhtman David A Herbst Max Shin Mark R Helmers Pavan Atluri Source Type: research

Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG Study
CONCLUSIONS: The PORTICO NG Study demonstrates low rates of adverse events and PVL up to 1 year in patients at high or extreme surgical risk, confirming the safety and efficacy of the Navitor THV system.PMID:36895190 | DOI:10.4244/EIJ-D-22-01108
Source: EuroIntervention - March 10, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Lars Sondergaard Antony S Walton Stephen G Worthley Dave Smith Bassem Chehab Ganesh Manoharan Gerald Yong Francesco Bedogni Nicholas Bates Michael J Reardon Source Type: research

Outcomes of Transcatheter Aortic Valve Replacement in Patients with Concomitant Aortic Regurgitation
CONCLUSIONS: TAVR can be safely performed in patients with mixed valvular disease, yielding comparable outcomes as in isolated AS.PMID:36791833 | DOI:10.1016/j.athoracsur.2023.02.008
Source: The Annals of Thoracic Surgery - February 15, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Sarah Yousef Valentino Bianco Dustin Kliner Catalin Toma Derek Serna-Gallegos David West Amber Makani Jianhui Zhu Floyd W Thoma James A Brown Takuya Ogami Ibrahim Sultan Source Type: research

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research

Pages: 1  2  3  4  5  6  7  8